{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% CI could not be calculated due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"1.4","upperLimit":"NA","value":"1.4"},{"comment":"Upper limit of 95% CI could not be calculated due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"1.3","upperLimit":"NA","value":"1.5"},{"comment":"Upper limit of 95% CI could not be calculated due to insufficient number of participants with events.","groupId":"OG002","lowerLimit":"1.4","upperLimit":"NA","value":"1.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Progression free survival was defined as time from start date of treatment to the date of first documentation of PD or death due to any cause. PD was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm and unequivocal progression of pre-existing lesions. 95% CI was based on Brookmeyer and Crowley method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with any advanced or metastatic solid tumor indications with approved therapies using immune checkpoint inhibitors or anti-vascular endothelial growth factor agents were administered PF-07263689 at a dose 2\\*10\\^8 plaque forming unit (PFU) once weekly for 4 weeks as an intravenous (IV) push. Participants were followed up for up to 90 days post-last dose of study treatment. Participants were followed up for survival until death, withdrawal of consent, or end of the study.","id":"OG000","title":"Part 1A PF-07263689 2*10^8 PFU"},{"description":"Participants with any advanced or metastatic solid tumor indications with approved therapies using immune checkpoint inhibitors or anti-vascular endothelial growth factor agents were administered PF-07263689 at a dose 6\\*10\\^8 PFU once weekly for 4 weeks as an IV push. Participants were followed up for up to 90 days post-last dose of study treatment. Participants were followed up for survival until death, withdrawal of consent, or end of the study.","id":"OG001","title":"Part 1A PF-07263689 6*10^8 PFU"},{"description":"Participants with any advanced or metastatic solid tumor indications with approved therapies using immune checkpoint inhibitors or anti-vascular endothelial growth factor agents were administered PF-07263689 at a dose 20\\*10\\^8 PFU once weekly for 4 weeks as an IV push. Participants were followed up for up to 90 days post-last dose of study treatment. Participants were followed up for survival until death, withdrawal of consent, or end of the study.","id":"OG002","title":"Part 1A PF-07263689 20*10^8PFU"}],"paramType":"MEDIAN","populationDescription":"Full analysis set included all enrolled participants. Data is not reported for Part 1b as no participants were enrolled and data was not collected.","reportingStatus":"POSTED","timeFrame":"From start date of treatment to the date of first documentation of PD or death due to any cause (up to maximum follow-up of 10.45 months)","title":"Part 1: Progression Free Survival","type":"SECONDARY","unitOfMeasure":"Months"}